Another notable agent is JNJ-61610588 (CI-8993), a humanized monoclonal antibody against VISTA developed by Janssen, currently being tested in early-phase clinical trials (e.g., NCT04475523) for advanced cancers (172, 174, 175). The gene discussed is VSIR; the disease is cancer.